What antihypertensive medications are recommended for managing hypertension in a patient with chronic kidney disease, including dosing and monitoring?

Antihypertensive Medication in CKD

For patients with CKD and hypertension, start with an ACE inhibitor or ARB (especially if proteinuria is present), target blood pressure <130/80 mmHg, and add thiazide or loop diuretics as second-line therapy, with most patients requiring combination therapy to reach target.

Blood Pressure Targets

The target BP for CKD patients is <130/80 mmHg 1, 2, 3. The most recent KDIGO 2021 guideline suggests an even more aggressive target of <120 mmHg systolic when tolerated, using standardized office BP measurement 3. However, this intensive target should be applied cautiously—avoid it in patients with very limited life expectancy or symptomatic postural hypotension.

First-Line Medication Selection

For Proteinuric CKD (ACR ≥30 mg/mmol or protein ≥500 mg/24h):

ACE inhibitors are the first-line choice (Grade A evidence) 1, 2, 1. If ACE inhibitors are not tolerated, use ARBs (Grade B evidence) 1, 2. This applies to both diabetic and non-diabetic CKD patients with significant albuminuria 3.

The KDIGO 2021 guideline specifically recommends:

• RAS inhibitors for CKD G1-G4 with severely increased albuminuria (A3) without diabetes (Grade 1B)
• RAS inhibitors for CKD G1-G4 with moderately-to-severely increased albuminuria (A2-A3) with diabetes (Grade 1B) 3

For Non-Proteinuric CKD:

While RAS inhibitors may still be reasonable 3, the evidence is less compelling. The 2020 ISH guidelines recommend starting with ACE inhibitors/ARBs for non-Black patients or ARBs with calcium channel blockers for Black patients 4.

Second-Line and Combination Therapy

Thiazide diuretics are recommended as additive therapy (Grade D) 1, 2, 1. This is critical because sodium retention plays a central role in CKD-related hypertension.

Switch to loop diuretics when:

• eGFR <30 mL/min/1.73m² 5
• Volume overload is present 1, 2

Most patients will require combination therapy (typically 2-3 drugs) to reach target BP 1, 2. The typical sequence is:

1. ACE inhibitor or ARB (maximized to highest tolerated dose)
2. Add thiazide diuretic (or loop diuretic if eGFR <30)
3. Add calcium channel blocker if needed
4. Consider spironolactone for resistant hypertension 4

Critical Dosing and Monitoring

Use the highest approved dose of ACE inhibitors/ARBs that is tolerated, as trial benefits were achieved at these doses 3.

Monitor within 2-4 weeks of initiation or dose increase:

• Serum creatinine
• Serum potassium
• Blood pressure 3

Continue ACE inhibitor/ARB unless:

• Serum creatinine rises >30% within 4 weeks 3
• Symptomatic hypotension occurs
• Uncontrolled hyperkalemia despite medical management
• eGFR <15 mL/min/1.73m² with uremic symptoms 3

Important Contraindications and Cautions

Never combine ACE inhibitor + ARB + direct renin inhibitor (Grade 1B) 3. The combination of ACE inhibitor and ARB is specifically not recommended for non-proteinuric CKD (Grade B) 1, 2, 6.

Exercise caution with ACE inhibitors/ARBs in:

• Bilateral renal artery stenosis
• Unilateral stenosis with solitary kidney
• Risk of acute renal failure 1, 2

Managing Hyperkalemia

Do not automatically stop RAS inhibitors for hyperkalemia. Instead, employ strategies to reduce potassium levels 3:

• Low potassium dietary counseling
• Oral potassium binders
• Adjust other medications contributing to hyperkalemia

This approach preserves the prognostic benefits of RAS inhibition.

Emerging Therapies

Recent evidence supports adding:

• SGLT2 inhibitors for patients with proteinuric CKD, with or without diabetes 7, 8
• Finerenone (nonsteroidal mineralocorticoid receptor antagonist) for type 2 diabetes with CKD 8

These provide additional cardio-renal protection beyond BP lowering alone.

Common Pitfalls to Avoid

1. Don't use DASH diet or potassium-rich salt substitutes in advanced CKD due to hyperkalemia risk 3
2. Don't use thiazides alone when eGFR <30—switch to loop diuretics 5
3. Don't stop RAS inhibitors prematurely for modest creatinine rises (<30%) or manageable hyperkalemia 3
4. Don't apply intensive BP targets to non-standardized measurements—this is potentially hazardous 3
5. Avoid direct arterial vasodilators (hydralazine, minoxidil) as they don't provide renal protection 1